Actively Recruiting
Albumin-bound Paclitaxel Combined With Gemcitabine First-line Inoperable Pancreatic Cancer
Led by Tianjin Medical University Cancer Institute and Hospital · Updated on 2021-09-21
934
Participants Needed
1
Research Sites
296 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
This study aims to further observe and evaluate whether the three-week administration of albumin-bound paclitaxel combined with gemcitabine is equivalent to the four-week administration in the treatment of inoperable locally advanced or metastatic pancreatic cancer
CONDITIONS
Official Title
Albumin-bound Paclitaxel Combined With Gemcitabine First-line Inoperable Pancreatic Cancer
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Age 18 years or older, any gender
- Diagnosed with inoperable locally advanced or metastatic pancreatic cancer (except islet cell carcinoma) by pathology or histology
- No prior standard systemic treatment, or more than six months since postoperative treatment ended
- At least four weeks since major surgery or radiotherapy, with no local treatment to metastases
- At least one measurable lesion by CT scan
- Normal main organ function meeting specified blood and biochemical standards
- Voluntarily consented to participate and able to comply with follow-up
You will not qualify if you...
- Pregnant or breastfeeding women
- History or presence of other malignant tumors except cured skin basal cell carcinoma or cervical carcinoma in situ
- Known allergy to albumin-bound paclitaxel, gemcitabine, or their excipients
- Clinically significant ascites
- Arterial or venous thrombosis within past six months
- Active hepatitis B or C infection
- Considered unsuitable for the study by a doctor
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Rui Liu
Tianjin, Tianjin Municipality, China, 300000
Actively Recruiting
Research Team
L
Liu rui, professor
CONTACT
J
Ji zhi, professor
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
2
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here